Biofrontera Inc (BFRI)

Currency in USD
0.9300
-0.0586(-5.93%)
Real-time Data·
BFRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.92000.9700
52 wk Range
0.53601.1900
Key Statistics
Prev. Close
0.9886
Open
0.95
Day's Range
0.92-0.97
52 wk Range
0.536-1.19
Volume
165.66K
Average Volume (3m)
161.82K
1-Year Change
32.8668%
Book Value / Share
0.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BFRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.0000
Upside
+545.16%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Biofrontera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.0000
(+545.16% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy3.00+222.58%3.00MaintainNov 14, 2025
Benchmark
Buy3.00+222.58%3.00MaintainOct 03, 2025
Benchmark
Buy2.75+195.70%7.00MaintainMay 19, 2025

Biofrontera Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue rose 17% YoY to $10.1M; gross margin expanded to 80% from 62%, driven by strategic transaction with Biofrontera AG.
  • Net loss improved to $4.8M ($0.41/share) vs $4.2M ($0.47/share) in Q1 2025; operating expenses increased 10% due to higher SG&A costs.
  • Stock fell 2.9% in premarket despite 68% YTD gain; company faces going concern qualification due to potential liquidity challenges.
  • FY2026 revenue guidance set at $46.76M; expects Q4 2026 profitability with $0.21 EPS after losses in Q2-Q3; FY2027 revenue forecast at $54.7M.
  • FDA approval for Ameluz superficial basal cell carcinoma indication expected by Sept 28, 2026; potential tariff risks on European imports cited.
Last Updated: 14/05/2026, 16:44
Read Full Transcript

Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
0.48 / 0.41
Revenue / Forecast
17.1M / --
EPS Revisions
Last 90 days

BFRI Income Statement

Compare BFRI to Peers and Sector

Metrics to compare
BFRI
Peers
Sector
Relationship
P/E Ratio
−1.1x−23.0x−0.5x
PEG Ratio
−0.02−0.260.00
Price/Book
1.1x1.1x2.6x
Price / LTM Sales
0.3x2.4x3.2x
Upside (Analyst Target)
-132.3%50.4%
Fair Value Upside
Unlock31.4%7.2%Unlock

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Employees
89

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
176.60K1.52%174.58K
Other Institutional Investors
4.99M42.87%4.94M
Public Companies & Retail Investors
6.48M55.62%6.40M
Total
11.65M100.00%11.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rosalind Advisors, Inc.9.79%1,140,7641,128
Rosalind Master Fund L.P.9.79%1,140,7641,128

People Also Watch

3.995
ATAI
-1.11%
4.960
CNSP
-1.00%
2.2100
DARE
-22.73%
0.228
OTLK
-2.06%
0.818
RNXT
-4.29%

FAQ

What Is the Biofrontera (BFRI) Stock Price Today?

The Biofrontera stock price today is 0.9300 USD.

What Stock Exchange Does Biofrontera Trade On?

Biofrontera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biofrontera?

The stock symbol for Biofrontera is "BFRI."

What Is the Biofrontera (BFRI) Afterhours Price Today? (Afterhours variable test: 0.9900) Current Date: May 15, 2026

After hours price: 0.9900. After hours price change (units): 0.0014. Price change percentage: 0.1400%

What Is the Biofrontera Market Cap?

As of today, Biofrontera market cap is 11.8700M USD.

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -1.0358.

From a Technical Analysis Perspective, Is BFRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biofrontera Stock Split?

Biofrontera has split 1 times.

How Many Employees Does Biofrontera Have?

Biofrontera has 89 employees.

What is the current trading status of Biofrontera (BFRI)?

As of May 15, 2026, Biofrontera (BFRI) is trading at a price of 0.9300 USD, with a previous close of 0.9886 USD. The stock has fluctuated within a day range of 0.9200 USD to 0.9700 USD, while its 52-week range spans from 0.5360 USD to 1.1900 USD.

What Is Biofrontera (BFRI) Price Target According to Analysts?

The average 12-month price target for Biofrontera is 6.0000 USD, with a high estimate of 9 USD and a low estimate of 3 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +545.16% Upside potential.

What Is the BFRI Premarket Price?

BFRI's last pre-market stock price is 0.9915 USD. The pre-market share volume is 5,250.0000, and the stock has decreased by 0.0029, or 0.2900%.

What Is the BFRI After Hours Price?

BFRI's last after hours stock price is 0.9900 USD, the stock has decreased by 0.0014, or 0.1400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.